AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Tiziana Life Sciences will participate in BIO-Europe 2025 as a presenting company, showcasing its nasal delivery platform and lead candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody. The event takes place in Vienna, Austria, from November 3-5, 2025, and will include one-on-one partnering meetings with biopharma executives and investors.
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet